<DOC>
	<DOC>NCT00932217</DOC>
	<brief_summary>To evaluate the difference in the incidence of febrile episodes in patients undergoing stem cells mobilization with chemotherapy and filgrastim versus chemotherapy and lenograstim. A febrile episode will be considered as: body temperature &gt; 38°C for two measurements in the 24 hours with an interval of 6 hours at least between the two measurements.</brief_summary>
	<brief_title>Study on the Incidence of Febrile Episodes During Stem Cells Collection After Chemotherapy in Patients With Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>1. Age &gt; 18 and &lt; 70 years 2. Diagnosis of multiple myeloma 3. ECOG &lt; 2 to be evaluated at baseline, after the induction chemotherapy 4. Indication to the mobilization with high dose cyclophosphamide chemotherapy 5. Normal blood counts: neutrophils &gt; 1500/μl; platelets &gt; 100.000/μl; hemoglobin &gt; 10 g/dl. 6. Liver and renal function: SGOT/AST, SGPT/ALT; bilirubin &lt; 1.5 times the upper limit of the normal ranges; creatinine &lt; 2 times the upper limit of the normal ranges. 7. Interval from previous induction chemotherapy to high dose chemotherapy between 30 and 60 days 8. ECG e/o Echocardiogram within age related normal range 9. Negative HCV and HbsAg 10. Must be willing and able to fill in the patient's diary 11. Written informed consent 1. Documented and/or suspected infections 2. Uncontrolled concurrent illness 3. Documented cardiac dysfunction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2009</verification_date>
</DOC>